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DOI 10.1016/j.chembiol.2007.04.003Pain is one of the body’s main warning
systems, but when nerves malfunc-
tion, they may spontaneously amplify
benign stimuli such as heat, cold, and
light pressure, generating pain signals.
This becomes a debilitating condition
known as neuropathic pain, usually as-
sociated with nerve trauma or dis-
eases such as diabetic neuropathy,
multiple sclerosis, viral infections, or
the course of cancer chemotherapy.
It can also follow injury to the spinal
cord or damage from a stroke. Recent
studies suggest that the functional
pain disorder fibromyalgia also has
a neuropathic pain component.
Neuropathic pain can also emerge
when ‘‘you lose a limb,’’ said Allan
Basbaum, Ph.D., professor and chair
of the Department of Anatomy, Univer-
sity of California, San Francisco. ‘‘Ev-
erybody has a phantom. But in about
20% of people, the phantom doesn’t
disappear. Instead, patients are left
with severe pain in the phantom limb.
The pain arises from a combination of
hyperactivity of the damaged nerves
in the stump and a maladaptive alter-
ation of nervous system circuits in the
central nervous system (spinal cord
and brain).’’ According to Basbaum,
neuropathic pain may eventually re-
solve in some people, but it is often
a chronic condition.
While a roster of drugs including opi-
oids and nonsteroidal anti-inflamma-
tories are deployed for the acute, in-
flammatory pain that occurs after
injury or surgery, people who suffer
from neuropathic pain have fewer op-
tions. First-line drugs such as anticon-
vulsants, local anesthetics, and some
types of antidepressants are of limited
effectiveness.
Treatment by Trial and Error
‘‘In all those classes, the very best [pa-
tient] response rate is one in three,’’
said Dr. Clifford Woolf, M.D., Ph.D.,
professor of anesthesia research, De-
partment of Anesthesia and Critical
Care at Massachusetts General Hos-
pital and Harvard Medical School.
‘‘We have no predictors of who comes
into the office, who will respond. There
is a big gap in our knowledge.’’
All the pharmaceutical companies
and many biotechs have discovery
programs aimed at various pain tar-
gets including cation channels, neural
transmission and signaling pathways
(kinases). ‘‘In some cases, neuropathic
pain may have a neurodegenerative
component,’’ Woolf said. ‘‘There are
multiple mechanisms that operate. The
solutions can be diverse as well.’’ Re-
search by Alameda, California-based
Avigen (http://www.avigen.com) and
Neuromed (http://www.neuromed.
com) in Vancouver, British Columbia,
may offer some novel alternatives in
the near future.
Balancing the Immune
and Neural Responses
Avigen estimates the chronic pain relief
market in the U.S. and Europe to be
worth about $3 billion. The company
While a roster of drugs including opioids and nonsteroidal
anti-inflammatories are deployed for the acute, inflamma-
tory pain that occurs after injury or surgery, people who
suffer from neuropathic pain have fewer options.Chemistry & Biology 14, April 2007 ªhopes its lead product, AV411, a small
molecule oral drug for neuropathic
pain, can take a share. AV411 attenu-
ates the signaling function of the
spine’s glial cells. Its generic name is
ibudilast (3-isobutyryl-2-isopropylpyr-
azolo[1,5-a]pyridine). A nonselective
phosphodiesterase (PDE) inhibitor
approved in Japan for treatment of
bronchial asthma and post-stroke
dizziness, ibudilast (now off-patent)
inhibits the production of pro-inflam-
matory cytokines, including tumor
necrosis factor a and interleukin 1b,
and increases output of anti-inflamma-
tory cytokine interleukin 10 (IL-10) as
well as certain neurotrophic factors.
Pro-inflammatory cytokines are a
family of proteins released by activated
immune cells that communicate with
white blood cells. Another company,
MediciNova, is testing ibudilast in
Eastern Europe as a treatment for
multiple sclerosis. AV411 is now in a
phase II trial in Australia (which recog-
nizes Japanese drug designations),
and is undergoing a phase I trial in
the U.S.
According to Dr. Linda Watkins, pro-
fessor and researcher in the University
of Colorado at Boulder’s Psychology
Department and Center for Neurosci-
ence, some pain is simply not attribut-
able to nerve damage. Moreover,
some patients do not respond to opi-
ates, which work directly on the pain
centers in the brain. ‘‘We started with
the idea that there was another
player,’’ said Watkins. Building upon
research by Garrison and colleagues
from the 1990s showing that astro-
cytes and microglia in the spinal cord
were activated by damage to the sci-
atic nerve and caused neuropathic
pain symptoms, Watkins’s group
found that pain triggers glial cells to re-
lease a cascade of pro-inflammatory
cytokines [1].2007 Elsevier Ltd All rights reserved 341
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vice president of research and devel-
opment at Avigen, stimulated glial
cells produce pro-inflammatory cyto-
kines and chemokines such as IL-1,
IL-6, IL-8, and MCP-1. Natural coun-
terbalances include IL-1 receptor
antagonist and IL-10. An anti-inflam-
matory regulator for many of the pro-
inflammatory cytokines, IL-10 reduces
glial activation and attenuates chronic
pain. Johnson’s group looked for an
oral pharmaceutical that would dupli-
cate these effects and found it in
ibudilast.
That Burning Sensation
Founded in 1992, Avigen, a public
company, focused on gene therapy
for its first decade but concluded that
it wouldn’t work fast enough to make
the fortunes of a small company. In
2003, Avigen faced a crossroads. Ken
Chahine, Ph.D, J.D., Avigen president
and CEO, lobbied the board to divest
itself of the gene therapy business be-
fore they burned through all of their
cash. They sold their Parkinson’s dis-
ease and hemophilia intellectual prop-
erty to Genyzme for $12 million in
cash up front and milestone payments.
To replace its pipeline, Avigen focused
on acquiring small molecule and bio-
logical neurology products.
In 2006, the company in-licensed
formulations of AV650, (tolperisone),
a nonsedating drug approved in Eu-
rope for neuromuscular spasms and
spasticity caused by spinal cord injury
and multiple sclerosis, from Sanoche-
mia. Avigen is developing the drug
into a slow-release formulation, so
that patients can sleep through the
night without muscle spasms. So far,
Avigen has conducted a 12 week
phase I safety and efficacy trial.
Broadening their pipeline, Avigen’s
AV513, a sulfated carbohydrate for he-
mophilia A and B, is entering clinical
trials. The company intends to bring
AV513 to phase II and then license it
to a pharmaceutical company. AV333
is a preclinical, plasmid-based DNA
therapy that when injected into the spi-
nal cord induces production of IL-10.
‘‘It is not an insignificant candidate
because its efficacy is substantial
for intractable chronic pain,’’ says
Johnson.342 Chemistry & Biology 14, April 2007 ªNewly restyled, Avigen’s burn rate of
$18 million in 2005 and 2006 is ex-
pected to rise to about $20 million in
2007, due to the clinical trials the com-
pany is conducting. ‘‘A key thing is to
make decisions when you still have
money,’’ said Chahine. ‘‘You need
some runway.’’ At the end of 2006,
Avigen received another $19 million
from a private placement with inves-
tors, bringing the company to about
$70 million in cash in the bank, off-set-
ting an accumulated deficit of $195
million.
For Neuromed, Blocking
Channels Is Blocking Pain
North of the border, Neuromed makes
small molecule drugs based on what
the company terms a selective calcium
channel inhibitor. Neuromed looks at
two of the five pharmacological clas-
ses of calcium channels found in the
body for analgesia: N-type in the ner-
vous system and T-type in the heart
and nervous system.
Neuromed was launched in 1994,
but the company’s turning point was
a major licensing deal with Merck in
2006 for its N-type channel inhibitors,
consisting of $25 million up front and
a potential $450 million in milestone
payments, the largest such deal ever
for a Canadian biotech. Neuromed’s
lead compound, NMED-160 (MK-
6721), now in phase II development
for the treatment of neuropathic pain,
is not expected to hit the market be-
fore 2011. Neuromed is also internally
developing T-type channel inhibitors.
According to Dr. Christopher Gallen,
Neuromed president and CEO, drugs
like Procardia (Nifedipine), a channel
blocker taken for high blood pressure,
were identified in the 1970s and 80s
by serendipity, but because nobody
knew how to design selective calcium
channel blockers, there was not a sec-
ond crop of follow-on molecules. The
company’s intellectual property is
based on the work of Dr. Terrance
Snutch, professor in the Departments
of Zoology and Psychiatry and the
Brain Research Centre at University of
British Columbia and chief scientific
officer at Neuromed. Snutch cloned
the genes encoding the various cal-
cium channels important in the brain
and heart. Because the crystal struc-2007 Elsevier Ltd All rights reservedtures of these channel proteins are
unknown and the requirement for
patch clamp electrophysiology assays
made it impossible to do mass library
screening, Snutch developed what be-
came Neuromed’s compounds by ex-
amining known inhibitors and finding
a common pharmacophore. It took
several years for Snutch to learn how
to reverse engineer molecules to
produce blockers selective for the N-
type and the three T-type calcium
channels.
Watch Out for That Snail
Ziconotide (Prialt), a painkiller mar-
keted by Elan Pharmaceuticals, set
the stage for developing channel
blockers as analgesics. [2] Prialt’s ac-
tive ingredient is a synthetic version of
a peptide derived from a conotoxin
found in the venom of theConusmagus
snail (see cover of this issue); it is the
first N-type channel antagonist that
worked powerfully against both neuro-
pathic and inflammatory pain. How-
ever, as a large protein, Prialt needs
to be injected into the spine with
a pump. It also causes loss of muscular
coordination, delirium, and psychosis
in patients, as well as influencing blood
pressure. To develop a small molecule,
oral drug that would relieve pain with
fewer side effects, Snutch designed a
small molecule that selectively blocks
the N-type calcium channel when it is
in the configuration it assumes when
highly stimulated by pain.
Neuromed was initially funded by lo-
cal Vancouver venture capitalists and
later involved U.S. venture capitalists
in the Series C round led by MPM Cap-
ital. The company has undergone four
rounds of financing for a total of U.S.
$74 million. The company currently
has about $50 million in the bank and
remains privately held.
Pinpointing Where It Hurts
Over the next few decades, the real
hope for treating neuropathic pain pa-
tients is the ability to determine which
drugs will work for individuals. ‘‘One
(issue) is to better understand the
mechanisms of neuropathic pain, par-
ticularly the pathophysiology,’’ said Dr.
David Simpson, director, Clinical Neu-
rophysiology Laboratories, Neuro-
AIDS Program, Mount Sinai Medical
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understand the particular disease
state.whether we can identify or not
the specific mechanism in neuropathic
pain in a specific patient. There may be
more than one mechanism in a disease
or even in a given patient, but right now
we don’t have those tools available toidentify those mechanisms that are
operative in a given patient’s pain syn-
drome.’’ With the goal of treating every
pain patient, not just one in three, com-
panies like Avigen and Neuromed are
exploring these questions, and
pharma companies are lining up to in-
vest in promising answers.Chemistry & Biology 14, April 2007 ªREFERENCES
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